Found 150 clinical trials
Conservative vs Surgical Treatment of Trigonocephaly Craniofacial Surgery in Children With Trigonocephaly
conservatively or surgically. OUTCOME MEASURES Primary: Head growth decline, indicating raised intracranial pressure Secondary: fundoscopy, cognition, behavior, refraction and vision, forehead shape
- 0 views
- 03 Dec, 2024
- 2 locations
Study of Skin Tumors in Tuberous Sclerosis
Tuberous sclerosis is a rare, hereditary disease in which patients develop multiple tumors. Although not cancerous, the tumors can affect various organs, including the heart, lungs, kidneys, skin
- 0 views
- 22 Nov, 2024
- 1 location
Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors
This is Phase 1/Phase 2, open label, multiple cohort, first-in-human study to evaluate safety, PK, PDy and efficacy of SAR444200 as a monotherapy or in combination with other anti-cancer agents
- 0 views
- 03 Dec, 2024
- 13 locations
BIVV020 (SAR445088) n Prevention and Treatment of Antibody-mediated Rejection (AMR)
>
Secondary Objectives:
<ul>- 0 views
- 03 Dec, 2024
- 28 locations
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
scheduleul>
Secondary Objective:
<ul>- 0 views
- 01 Mar, 2024
- 21 locations
Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa
participants with IOPD.
- 0 views
- 18 Apr, 2025
- 16 locations
Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe
, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b [DTaP-IPV-HB-Hib vaccine]) to infants and toddlers 6 weeks to 18 months old
Secondary objectives are:
<ul>- 0 views
- 06 Feb, 2025
- 1 location
Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
-term safety and efficacy of amlitelimab in treated participants with age ≥12 years old with moderate to severe AD.
The study duration per participant will be up to 180 weeks, including:
<ul- 0 views
- 28 Apr, 2025
- 110 locations
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the
- 0 views
- 03 Jul, 2025
- 26 locations
A randomized, double-blind study to test an oral medicine, Belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagnosed chronic graft versus host disease.
This study is looking for individuals at least 12 years of age with newly diagnosed graft versus host disease after cell transplantation. Chronic graft versus host disease (cGVHD) is an immune-mediated and fibrotic disorder involving many organs, where the transplanted donor cells attack the transplant recipient’s body, after a stem …
- 0 views
- 03 Dec, 2024
- 58 locations